Search

Background: To evaluate the effects of vitamin D (vitD) supplement on uterine fibroid growth. Materials and Methods: A randomized blinded clinical trial was conducted at a tertiary university-based hospital from August 2017 to September 2018. Totally, 204 women were enrolled into the study. They had at least one uterine fibroid >10 mm on transvaginal ultrasound and their vitD level was insufficient (i.e. 20-30 ng/ml). The intervention group was treated with vitD 50000 U supplements for two months. After 2 months, ultrasound screening and vitD level measurement was done in both groups. Results: At first, the mean serum vitD levels in intervention and control group were 23.62 and 23.20 ng/ml, respectively. After 8 weeks, the mean serum vitD levels in the control and intervention group were 22.72 and 28.56 ng/ml respectively (P<0.05). Also, mean fibroma diameter in the intervention group before and after 8 weeks of vitD supplementation was 43 ± 4.68 and 42.6 ± 1.31 mm, respectively. Mean uterine fibroid diameter in the control group which did not receive vitD supplements, before and after 8 weeks was 41.98 ± 5.25 and 47.81 ± 3.42 mm, respectively. The variation in the mean size of the uterine fibroid between the control and intervention group which was respectively about 5.83 mm increase and 0.48 mm decrease, was significant (P<0.001). Conclusion: Our results showed that vitD supplementation prevents fibroid growth. It seems that vitD supplement is a simple, safe and inexpensive modality for leiomyoma growth prevention (Registration number: IRCT201703122576N15). [ABSTRACT FROM AUTHOR]

Ovarian Hyperstimulation Syndrome (OHSS) is a serious complication of Assisted Reproductive Technology (ART). Some studies show that intravenous calcium infusion decreases the risk of OHSS in high-risk patients. Some life-threatening complications may occur following intravenous calcium gluconate infusion, but oral calcium carbonate is a cheap and easy-to-use medication with no/minor side-effects. The present clinical trial was therefore designed to identify the role of oral calcium in OHSS prevention in high-risk patients. A total of 99 patients who had received an antagonist protocol for ovarian stimulation in their ART cycles and were at risk of OHSS were recruited for the study. The patients were allocated into two groups to receive either 500-mg BID calcium carbonate tablets or placebo tablets from their puncture date for five days. The findings showed no significant differences in oocyte and grade A, B and C embryo counts between the two groups. Moreover, the clinical pregnancy rate and the frequency of OHSS symptoms were not significantly different between the two groups. The frequencies of mild, moderate and severe OHSS were not significantly different between the two groups either. Since oral calcium is an easy-to-use method with limited side-effects, we recommend further studies to examine its effects on OHSS prevention in high-risk patients. [ABSTRACT FROM AUTHOR]

Background: To evaluate the effects of vitamin D (vitD) supplement on uterine fibroid growth., Materials and Methods: A randomized blinded clinical trial was conducted at a tertiary university-based hospital from August 2017 to September 2018. Totally, 204 women were enrolled into the study. They had at least one uterine fibroid >10 mm on transvaginal ultrasound and their vitD level was insufficient (i.e. 20-30 ng/ml). The intervention group was treated with vitD 50000 U supplements for two months. After 2 months, ultrasound screening and vitD level measurement was done in both groups., Results: At first, the mean serum vitD levels in intervention and control group were 23.62 and 23.20 ng/ml, respectively. After 8 weeks, the mean serum vitD levels in the control and intervention group were 22.72 and 28.56 ng/ml respectively (P<0.05). Also, mean fibroma diameter in the intervention group before and after 8 weeks of vitD supplementation was 43 ± 4.68 and 42.6 ± 1.31 mm, respectively. Mean uterine fibroid diameter in the control group which did not receive vitD supplements, before and after 8 weeks was 41.98 ± 5.25 and 47.81 ± 3.42 mm, respectively. The variation in the mean size of the uterine fibroid between the control and intervention group which was respectively about 5.83 mm increase and 0.48 mm decrease, was significant (P<0.001)., Conclusion: Our results showed that vitD supplementation prevents fibroid growth. It seems that vitD supplement is a simple, safe and inexpensive modality for leiomyoma growth prevention (Registration number: IRCT201703122576N15)., Competing Interests: The authors declare no conflicts of interest., (Copyright© by Royan Institute. All rights reserved.)